Salénterprise increases its shareholding in NeoDynamics.
Through the exercise of its guarantee commitments for the recently carried out Rights Issue, Salénterprise has increased its shareholding to 39.5%.
NeoDynamics AB today announce that as a result of the Rights Issue, which was resolved by the Extraordinary General Meeting on 2 February 2024, Salénterprise has acquired 12,935,862 shares through its guarantee commitment. The increase in its holding now makes Salénterprise NeoDynamics largest shareholder.
For further information, please contact:
Matilda Salén, CEO NeoDynamics AB, phone 768 436 574 or e-mail matilda.salen@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone 735 972 011 or e-mail aaron.wong@neodynamics.com
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. NeoNavia® is CE approved, and in September 2022, received a 510k approval from the FDA. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
About NeoNavia®
NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.
About the pulse technology
The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.
For more information, please visit Neodynamics.com.